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Background: Data from previous studies indicate that optimal conditions for intubation are met 120 seconds after
administration of 0.15 mg.kg-1 cisatracurium (ED95 × 3) following the induction of anesthesia. The aim of this study
was to compare the doses required for complete paralysis after induction of anesthesia in ICU patients with the
dose used in patients undergoing elective surgery.
Methods: Seventeen ICU patients undergoing percutaneous tracheostomy and 17 patients undergoing an elective
surgical procedure under muscle relaxation were included. In both groups, an initial intravenous bolus of cisatracurium
besylate was given at a dose of 0.15 mg.kg-1 followed by repeated boluses of 0.03 mg.kg-1 every four minutes. The
objective was to obtain no response to the train-of-four (TOF). The contractile response of the corrugator supercilii
muscle was monitored every minute by observing the TOF in response to a peripheral nerve stimulator with a constant
current set to 60 mA.
Results: After the initial dose of cisatracurium, none of ICU patients (0/17) versus 15/17 of the elective surgery patients
were completely paralyzed (P < 0.0001). There was a delay in the onset of neuromuscular blockade among the ICU
patients. The cumulative doses of cisatracurium were significantly higher in the ICU group with 38 ± 14 mg (that is,
10 ± 4.7 ED95) versus 11 ± 2 mg (that is, 3 ± 0.3 ED95) in the elective surgery group (P < 0.0001).
Conclusion: The dosing of cisatracrurium for ICU patients, which is based on the dose recommended for elective
anesthesia, is unsuitable because the onset is too slow. This phenomenon is probably caused by changes in the
pharmacodynamics and pharmacokinetics. These data suggest that neuromuscular monitoring should be used in
the ICU.
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Although the use of neuromuscular blocking agents in the
ICU is still a matter of ongoing debate, they continue to
be frequently used. For example, in patients under volume
controlled ventilation, a transient curarization can be used
for brief diagnostic or therapeutic procedures in order to
avoid the hemodynamic consequences of deep sedation.
Also, in acute respiratory distress syndrome (ARDS)
patients, a prolonged curarization of 48 hours or more
is beneficial regarding systemic oxygenation, even in* Correspondence: minville.v@chu-toulouse.fr
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in any medium, provided the original work is ppatients well-adapted to their ventilator [1]. Because of
its pharmacokinetic properties, cisatracurium, a non-
depolarizing neuromuscular blocking agent of the benzy-
lisoquinoline family, is a popular choice in the ICU since
it is (at physiological pH and temperature) rapidly de-
graded by Hoffmann elimination, yielding two metabolites
without muscle relaxant properties: laudanosine and qua-
ternary monoacrylate. Impaired renal or liver function has
little influence on the pharmacokinetics of this drug [2,3].
The volume of distribution of cisatracurium is limited to
the extracellular fluid (144 mL.kg-1), total plasma clearance
is approximately 5.3 mL.min-1.kg-1, and the elimination half
life is between 22 and 30 minutes [4,5].
In both the ICU and during anesthesia, the train-of-four
(TOF) is the most widely used method of monitoringopen access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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is the dose required to produce a 95% twitch height de-
pression for the first twitch response of the adductor
pollicis muscle after stimulation of the ulnar nerve, and is
approximately 0.05 mg.kg-1 of body weight during
anesthesia with hypnotics and opioids (thiopental/midazo-
lam/fentanyl) [12,13]. Optimal conditions for intubation
are met 120 seconds after the administration of 0.15 mg.kg-1
cisatracurium (3 × ED95) during induction of anesthesia
(for 89 to 100% of patients) [14,15]. After administration
of 0.20 mg.kg-1 cisatracurium (4 × ED95), optimal condi-
tions are met within 90 seconds (for 95 to 100% of patients)
[15]. However, all the above studies were done on patients
scheduled for elective surgery and thus these recommen-
dations may not be appropriate for ICU patients where a
variety of factors can affect the pharmacokinetics and
pharmacodynamics of muscle relaxants: liver and/or kid-
ney failure; hypothermia; fluid and electrolyte imbalances
[16,17]; disorders of acid–base balance; as well as potential
drug interactions (for example, aminoglycosides, steroids)
[18]. This could indeed explain the observation that in
clinical practice, higher doses of cisatracurium are often
needed for ICU patients to obtain a clinically acceptable
degree of neuromuscular blockade (TOF = 0).
The aim of this study was to compare the doses required
for complete paralysis after induction of anesthesia in ICU
patients with the dose used in patients undergoing elective
surgery.
Methods
Thirty-four patients were enrolled in this prospective ob-
servational study. The study was performed in accordance
with the Helsinki Declaration. The Local Ethics Committee
(comité d’éthique de la recherche des Hôpitaux de
Toulouse: registration number 23–0412) approved the
study. Because there was neither a randomization involved
nor a change in the current local clinical practice (TOF
monitoring is part of the routine medical care in the ICU
and for surgical patients requiring a muscle relaxant), the
institutional review board waived the requirement for a
written informed consent.
Seventeen consecutive ICU patients who were para-
lyzed for a percutaneous tracheostomy were included.
The indication for the tracheostomy was an anticipated
length of mechanical ventilation for more than 15 days.
ICU patients were stable (no acute hepatic or renal failure),
euvolemic and on low dose catecholamine infusion
(norepinephrine < 1 mg.h-1).
The comparison group consisted of 17 consecutive
patients who were paralyzed for the anesthesia as part
of an elective surgical intervention. Exclusion criteria
included pregnancy, a history of significant neuromuscular
disease (multiple sclerosis; myasthenia gravis; muscu-
lar dystrophies), a known allergy to a non-depolarizingneuromuscular blocking agent, patients who received
neuromuscular blocking agents or were taking a treat-
ment known to influence the neuromuscular junction
(anticonvulsants; antidepressants; antihistamines). For
each patient, demographics and biological data were re-
corded. The creatinine clearance (CrCl) was assessed
by the simplified formula of the Modification of Diet in
Renal Disease (sMDRD) [19].
In all patients, (elective surgical patients as well as the
ICU patients) general anesthesia was induced with propofol
(2.5 to 3 mg.kg-1) and sufentanil (0.1 to 0.2 mg.kg-1) and an
initial bolus of cisatracurium at a dose of 0.15 mg.kg-1. This
was followed by a propofol infusion and repeated injections
of 0.03 mg.kg-1 cisatracrurium every four minutes until
complete muscle paralysis (TOF = 0) was achieved [20].
Monitoring of neuromuscular blockade was performed
using a peripheral nerve stimulator with constant current
using self-adhesive skin electrodes placed at the temporal
region. A current of 60 mA (rectangular stimulation, pulse
duration of 200 or 300 microseconds) was administered
four times (TOF) at a frequency of 2 Hz. An independent
observer monitored the TOF semi-quantitatively by
observing the contractile response of the corrugator
supercilii every minute. The criterion for muscle relax-
ation was a complete absence of any twitch response. Any
visible contraction was considered incomplete relaxation.
Statistical analysis
Based on a pilot study involving ten anesthetic patients
and ten ICU patients, we estimated that the difference
in dose to obtain adequate curarization was about 60%.
We calculated the number needed to find a difference of
60% in the dose of cisatracurium (in mg) with an alpha
of 5% and a power (1-beta) of 90% to be 16 patients in
each group.
Statistical analysis was performed using the software
StatView® (SAS Institute Inc., version 5.0, Cary, NC, USA).
Quantitative variables are presented as median (minimum-
maximum) and qualitative data are given as number and
percentage. Normal distribution of data was tested via the
Kolmogorov-Smirnov test. As data were not normally dis-
tributed, groups were compared by the Mann–Whitney
U-test for continuous variables and by Fisher’s exact test
for categorical variables.
Results
Demographic and biological data are presented in Table 1.
The reasons for ICU admission were: severe trauma (4);
septic shock (1); acute respiratory failure (7); cerebral
toxoplasmosis (1); aortic dissection (1); severe aortic sten-
osis (1); severe hyponatremia (1); and severe hypoglycemic
coma (1). The ICU patients had been ventilated for 12 ± 5
days before they were included in the present study. No
adverse cardiovascular events or signs of histamine release
Table 1 Demographic and biologic data
ICU patients Surgical patients
P
N = 17 N = 17
Age (years) 60 (28 to 83) 56 (26 to 86) 0.89
Sex (M/F) 13/4 11/6 0.88
Weight (kg) 75 (55 to 128) 71 (51 to 83) 0.076
Height (cm) 160 (144 to 175) 169 (158 to 186) 0.099
BMI 29 (27 to 39) 26 (22 to 37) 0.083
Urea (mmol.L-1) 10.9 (3.60 to 31) 6 (3.4 to 23.6) 0.02a
Creatinine (μmol.L-1) 84 (41 to 211) 88.50 (63.6 to 407) 0.67
Creatinine clearance
86.7 (29.8 to 159.4) 76.6 (13 to 113.4) 0.42
(ml.min-1.1.73 m2-1 )
Prothrombin rate 66 (20 to 89) 87 (64 to100) 0.001a
SGOT (IU.L-1) 40 (14 to 274) 34 (14 to 183) 0.33
SGPT (IU.L-1) 44 (15 to 425) 57 (13 to 293) 0.52
Protein (g.L-1) 55 (35 to 65) 71 (60 to 80) < 0.001a
Data are presented as median (minimum - maximum); aP < 0.05 using the
Mann–Whitney U-test.
Figure 2 Cumulative doses of cisatracurium for ICU (1) and
surgical patients (0). * = P < 0.05 using the Mann–Whitney U-test.
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cisatracurium.
After the initial dose of cisatracurium, none of ICU
patients (0/17) versus 15/17 anesthesia patients were
completely paralyzed (P < 0.0001).
The time to achieve complete neuromuscular blockade
(after the initial dose of 0.15 mg.kg-1 followed by repeated
injections of 0.03 mg.kg-1 every four minutes) was much
longer in ICU patients when compared to surgical patients:
34 ± 21 versus 4 ± 2 minutes respectively (P < 0.0001;
Figure 1) and the total cumulative dose of cisatracurium
was significantly higher in ICU patients when compared to
surgical patients: 38 ± 14 mg versus 11 ± 2 mg respectively
(P < 0.0001; Figure 2).Figure 1 Time of neuromuscular blockade for ICU (1) and
surgical patients (0). * = P < 0.05 using the Mann–Whitney U-test.Discussion
This is the first study comparing the dose of muscle relax-
ant needed between ICU patients and surgical patients. We
found that the time to achieve a complete neuromuscular
block after an initial dose of 0.15 mg.kg-1 followed by add-
itional smaller repeat doses was longer in ICU patients
when compared to surgical patients. We also showed that
the cumulative doses of cisatracurium required to obtain a
TOF = 0 were significantly higher in ICU patients.
The results observed in our surgical patients are consist-
ent with other published studies [12-14]. Increasing doses
of cisatracurium can shorten the time to obtain a TOF = 0
[12-14]. ICU studies regarding the pharmacokinetics and
pharmacodynamics of cisatracurium focused on patients
receiving continuous infusions of cisatracurium [1] and
mostly described the recovery profiles after continuous
administration [21,22]. The doses used in those publica-
tions were a bolus of 0.1 mg.kg-1 (2 × ED95) with an aver-
age rate of infusion of 2.6 mg.kg-1.min-1 (0.15 mg.kg-1.h-1)
or 3.2 mg.kg-1.min-1 (0.19 mg.kg-1.h-1) as required to ob-
tain a sufficient degree of neuromuscular blockade for
mechanical ventilation [21,22]. In comparison, the main-
tenance of muscle relaxation during anesthesia for a 95%
depression of muscle contraction has been shown to range
between 1.4 mg.kg-1.min-1 (0.08 mg.kg-1.h-1) [12] and
1.5 mg.kg-1.min-1 (0.09 mg.kg-1.h-1) [23]. This suggests
that the rate of continuous infusion required to obtain
muscle relaxation is greater in ICU patients when compared
to surgical patients.
The evaluation of cumulative dosing of neuromuscular
blocking agents is one method to determine dose–response
studies; however this method has limitations because the
elimination process begins while subsequent doses of cisa-
tracurium would continue to be administered and there-
fore recovery of neuromuscular blockade occurs during
re-administration of cisatracurium. No study has so far
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doses required to reach a maximum block after adminis-
tration of boluses of cisatracurium in ICU patients when
compared to surgical patients, but our results seem to be
consistent with those described for the continuous infusion
of muscle relaxants. In fact, the onset time may have been
shorter if ICU patients had received a higher initial bolus
dose. Thereby, our study only shows that in ICU patients
the initial dose 0.15 mg.kg-1 was not adequate.
In ICU patients, a change in pharmacokinetics of cisatra-
curium may explain slower onset of paralysis and the need
to administer larger doses. Indeed, Boyd et al. showed that
the volume of distribution (21.9 versus 9.2 L) and total
clearance (549 versus 293 mL.min-1) of cisatracurium are
higher in ICU patients when compared with anesthesia
[21], when the half-life of the drug remained unchanged
[21]. In ICU patients, an increased volume of distribution
could lead to a decrease in the concentration at the neuro-
muscular junction after the first dose and this may there-
fore explain the need to administer larger doses. Another
explanation could be a deregulation of acetylcholine recep-
tors in ICU patients [24]. This would involve qualitative
and quantitative changes of the acetylcholine receptor of
the neuromuscular junction [25]. An increase in the num-
ber of acetylcholine receptors (up-regulation), a prolifera-
tion of the receptors at the neuromuscular junction and the
rest of the muscle membrane, but also the formation of
neoreceptors were observed [24,26]. Neoreceptors differ
from the native receptor by substitution of the e-subunit by
the g-subunit [25] and are more resistant to the action of
nondepolarizing neuromuscular blocking [27]. The result is
a decreased sensitivity to nondepolarizing neuromuscular
blocking agents and a requirement for larger doses to
observe the same effect. This effect could in part explain
the findings in the present study since our ICU patients
had already been admitted and ventilated for 12 ± 5 days
before they were studied.
In ICU patients, many others factors could interfere
with the effect of neuromuscular blocking agents, for
example the presence of hypokalemia, hypercalcemia,
hypothermia, treatment with magnesium sulfate, and
so on. However, in our study, the ICU patients were
considered stable so these factors were unlikely to have
played a significant role. This should be taken into
account for future studies.
Our study has several limitations. First, in the absence
of pharmacokinetic data no definitive conclusion regarding
the etiology for the difference between groups can be
drawn from this report. Second, this was an observational
and not a randomized study.
Conclusion
In summary, the doses of cisatracurium for ICU patients
should be higher than those used in current anestheticpractice in order to achieve an adequate degree of
neuromuscular blockade. This phenomenon could be
related to changes in pharmacodynamics (deregulation
of receptors) and pharmacokinetics (increase in the
volume of distribution). Our data suggest that neuromus-
cular monitoring should be used to ensure a satisfactory
degree of neuromuscular blockade in ICU patients requir-
ing deep neuromuscular relaxation (TOF = 0) for surgical
procedures.
Further dose–response studies are required to determine
the optimal loading dose of cisatracurium in ICU patients.
Key messages:
 Repeated boluses and more time are necessary to
achieve complete muscle relaxation in ICU patients
if using the same dose as for the routine induction
of anesthesia.
 Doses of cisatracurium should be higher than those
used in current anesthetic practice for an adequate
degree of neuromuscular blockade.
 It seems reasonable to recommend monitoring
neuromuscular blockade in ICU patients.
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